Research ExplorerPublicationsReduced anoctamin 7 (ANO7) expression is a strong and indepe...

Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer

Standard

Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. / Marx, Andreas; Koopmann, Lena; Höflmayer, Doris; Büscheck, Franziska; Hube-Magg, Claudia; Steurer, Stefan; Eichenauer, Till; Clauditz, Till S; Wilczak, Waldemar; Simon, Ronald; Sauter, Guido; Izbicki, Jakob R; Huland, Hartwig; Heinzer, Hans; Graefen, Markus; Haese, Alexander; Schlomm, Thorsten; Bernreuther, Christian; Lebok, Patrick; Bonk, Sarah.

In: CANCER BIOL MED, Vol. 18, No. 1, 15.02.2021, p. 245-255.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Marx, A, Koopmann, L, Höflmayer, D, Büscheck, F, Hube-Magg, C, Steurer, S, Eichenauer, T, Clauditz, TS, Wilczak, W, Simon, R, Sauter, G, Izbicki, JR, Huland, H, Heinzer, H, Graefen, M, Haese, A, Schlomm, T, Bernreuther, C, Lebok, P & Bonk, S 2021, 'Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer', CANCER BIOL MED, vol. 18, no. 1, pp. 245-255. https://doi.org/10.20892/j.issn.2095-3941.2019.0324

APA

Marx, A., Koopmann, L., Höflmayer, D., Büscheck, F., Hube-Magg, C., Steurer, S., Eichenauer, T., Clauditz, T. S., Wilczak, W., Simon, R., Sauter, G., Izbicki, J. R., Huland, H., Heinzer, H., Graefen, M., Haese, A., Schlomm, T., Bernreuther, C., Lebok, P., & Bonk, S. (2021). Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. CANCER BIOL MED, 18(1), 245-255. https://doi.org/10.20892/j.issn.2095-3941.2019.0324

Vancouver

Marx A, Koopmann L, Höflmayer D, Büscheck F, Hube-Magg C, Steurer S et al. Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. CANCER BIOL MED. 2021 Feb 15;18(1):245-255. https://doi.org/10.20892/j.issn.2095-3941.2019.0324

Bibtex

@article{74652edb01de429bafc5c25a282415d8,
title = "Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer",
abstract = "Objective: Anoctamin 7 (ANO7) is a calcium2+-dependent chloride ion channel protein. Its expression is restricted to prostate epithelial cells. The exact function is unknown. This study aimed to analyze ANO7 expression and its clinical significance in prostate cancer (PCa).Methods: ANO7 expression was assessed by immunohistochemistry in 17,747 clinical PCa specimens.Results: ANO7 was strongly expressed in normal prostate glandular cells but often less abundant in cancer cells. ANO7 staining was interpretable in 13,594 cancer tissues and considered strong in 34.4%, moderate in 48.7%, weak in 9.3%, and negative in 7.6%. Reduced staining was tightly linked to adverse tumor features [high classical and quantitative Gleason grade, lymph node metastasis, advanced tumor stage, high Ki67 labeling index, positive surgical margin, and early biochemical recurrence (P < 0.0001 each)]. The univariate Cox hazard ratio for prostate-specific antigen (PSA) recurrence after prostatectomy in patients with negative vs. strong ANO7 expression was 2.98 (95% confidence interval 2.61-3.38). The prognostic impact was independent of established pre- or postoperatively available parameters (P < 0.0001). Analysis of annotated molecular data showed that low ANO7 expression was linked to TMPRSS2:ERG fusions (P < 0.0001), elevated androgen receptor expression (P < 0.0001), as well as presence of 9 of 11 chromosomal deletions (P < 0.05 each). A particularly strong association of low ANO7 expression with phosphatase and tensin homolog (PTEN) deletion may indicate a functional relationship with the PTEN/AKT pathway.Conclusions: These data identify reduced ANO7 protein expression as a strong and independent predictor of poor prognosis in PCa. ANO7 measurement, either alone or in combination, might provide clinically useful prognostic information in PCa.",
author = "Andreas Marx and Lena Koopmann and Doris H{\"o}flmayer and Franziska B{\"u}scheck and Claudia Hube-Magg and Stefan Steurer and Till Eichenauer and Clauditz, {Till S} and Waldemar Wilczak and Ronald Simon and Guido Sauter and Izbicki, {Jakob R} and Hartwig Huland and Hans Heinzer and Markus Graefen and Alexander Haese and Thorsten Schlomm and Christian Bernreuther and Patrick Lebok and Sarah Bonk",
note = "Copyright: {\textcopyright} 2021, Cancer Biology & Medicine.",
year = "2021",
month = feb,
day = "15",
doi = "10.20892/j.issn.2095-3941.2019.0324",
language = "English",
volume = "18",
pages = "245--255",
journal = "CANCER BIOL MED",
issn = "2095-3941",
publisher = "Chinese Anticancer Association",
number = "1",

}

RIS

TY - JOUR

T1 - Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer

AU - Marx, Andreas

AU - Koopmann, Lena

AU - Höflmayer, Doris

AU - Büscheck, Franziska

AU - Hube-Magg, Claudia

AU - Steurer, Stefan

AU - Eichenauer, Till

AU - Clauditz, Till S

AU - Wilczak, Waldemar

AU - Simon, Ronald

AU - Sauter, Guido

AU - Izbicki, Jakob R

AU - Huland, Hartwig

AU - Heinzer, Hans

AU - Graefen, Markus

AU - Haese, Alexander

AU - Schlomm, Thorsten

AU - Bernreuther, Christian

AU - Lebok, Patrick

AU - Bonk, Sarah

N1 - Copyright: © 2021, Cancer Biology & Medicine.

PY - 2021/2/15

Y1 - 2021/2/15

N2 - Objective: Anoctamin 7 (ANO7) is a calcium2+-dependent chloride ion channel protein. Its expression is restricted to prostate epithelial cells. The exact function is unknown. This study aimed to analyze ANO7 expression and its clinical significance in prostate cancer (PCa).Methods: ANO7 expression was assessed by immunohistochemistry in 17,747 clinical PCa specimens.Results: ANO7 was strongly expressed in normal prostate glandular cells but often less abundant in cancer cells. ANO7 staining was interpretable in 13,594 cancer tissues and considered strong in 34.4%, moderate in 48.7%, weak in 9.3%, and negative in 7.6%. Reduced staining was tightly linked to adverse tumor features [high classical and quantitative Gleason grade, lymph node metastasis, advanced tumor stage, high Ki67 labeling index, positive surgical margin, and early biochemical recurrence (P < 0.0001 each)]. The univariate Cox hazard ratio for prostate-specific antigen (PSA) recurrence after prostatectomy in patients with negative vs. strong ANO7 expression was 2.98 (95% confidence interval 2.61-3.38). The prognostic impact was independent of established pre- or postoperatively available parameters (P < 0.0001). Analysis of annotated molecular data showed that low ANO7 expression was linked to TMPRSS2:ERG fusions (P < 0.0001), elevated androgen receptor expression (P < 0.0001), as well as presence of 9 of 11 chromosomal deletions (P < 0.05 each). A particularly strong association of low ANO7 expression with phosphatase and tensin homolog (PTEN) deletion may indicate a functional relationship with the PTEN/AKT pathway.Conclusions: These data identify reduced ANO7 protein expression as a strong and independent predictor of poor prognosis in PCa. ANO7 measurement, either alone or in combination, might provide clinically useful prognostic information in PCa.

AB - Objective: Anoctamin 7 (ANO7) is a calcium2+-dependent chloride ion channel protein. Its expression is restricted to prostate epithelial cells. The exact function is unknown. This study aimed to analyze ANO7 expression and its clinical significance in prostate cancer (PCa).Methods: ANO7 expression was assessed by immunohistochemistry in 17,747 clinical PCa specimens.Results: ANO7 was strongly expressed in normal prostate glandular cells but often less abundant in cancer cells. ANO7 staining was interpretable in 13,594 cancer tissues and considered strong in 34.4%, moderate in 48.7%, weak in 9.3%, and negative in 7.6%. Reduced staining was tightly linked to adverse tumor features [high classical and quantitative Gleason grade, lymph node metastasis, advanced tumor stage, high Ki67 labeling index, positive surgical margin, and early biochemical recurrence (P < 0.0001 each)]. The univariate Cox hazard ratio for prostate-specific antigen (PSA) recurrence after prostatectomy in patients with negative vs. strong ANO7 expression was 2.98 (95% confidence interval 2.61-3.38). The prognostic impact was independent of established pre- or postoperatively available parameters (P < 0.0001). Analysis of annotated molecular data showed that low ANO7 expression was linked to TMPRSS2:ERG fusions (P < 0.0001), elevated androgen receptor expression (P < 0.0001), as well as presence of 9 of 11 chromosomal deletions (P < 0.05 each). A particularly strong association of low ANO7 expression with phosphatase and tensin homolog (PTEN) deletion may indicate a functional relationship with the PTEN/AKT pathway.Conclusions: These data identify reduced ANO7 protein expression as a strong and independent predictor of poor prognosis in PCa. ANO7 measurement, either alone or in combination, might provide clinically useful prognostic information in PCa.

U2 - 10.20892/j.issn.2095-3941.2019.0324

DO - 10.20892/j.issn.2095-3941.2019.0324

M3 - SCORING: Journal article

C2 - 33628598

VL - 18

SP - 245

EP - 255

JO - CANCER BIOL MED

JF - CANCER BIOL MED

SN - 2095-3941

IS - 1

ER -